NDAORALTABLET
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
33
Mechanism of Action
Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
Started Nov 2021
6 enrolled
Relapsed Follicular LymphomaRefractory Follicular Lymphoma
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Started Mar 2021
238 enrolled
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Rituximab, Idelalisib, and Venetoclax in Relapsed/Refractory CLL/SLL
Started Oct 2020
0Chronic Lymphocytic LeukemiaCLLRelapsed CLL+6 more
Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents
Started Jun 2019
0Diffuse Large B-Cell LymphomaMediastinal B-cell Lymphoma
Immune Response to Influenza Vaccine in Adults With B-cell Malignancies Treated With Idelalisib
Started Oct 2018
2 enrolled
B-cell Malignancies
Loss of Exclusivity
LOE Date
Sep 2, 2033
91 months away
Patent Expiry
Sep 2, 2033